Fairvalue-Calculator Fairvalue-Calculator
EN DE

Liaoning Chengda Biotechnology Co (688739) Fair Value & Analysis

Healthcare · CN · Market cap 8.3B CNY

Price¥19.93
Fair Value¥15.31
Upside-23.2%
Quality95/100
Evidence: High Range ¥14.79 – ¥17.84

Analysis

Liaoning Chengda Biotechnology Co (688739) currently trades at ¥19.93, while our model-based Fair Value estimate is ¥15.31 — implying the stock looks roughly 23.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Liaoning Chengda Biotechnology Co.,Ltd. a biotechnology company, engages in the research and development, production, and sales of vaccines for human use worldwide. It offers inactivated Japanese encephalitis vaccine (IJEV) and SPEEDA-rabies vaccine. The company's rabies and influenza vaccines are in the new drug application stage; haemophilus influenzae type b vaccine in phase III; recombinant human papillomavirus 15-valent vaccine is in phase II; and 13-valent pneumococcal polysaccharide conjugate and varicella, as well as the live meningococcal A, C, Y and W-135 conjugate vaccine are in phase I. Its Serogroup B meningococcal outer membrane vesicle, 20-valent pneumococcal polysaccharide conjugate, recombinant zoster vaccine, multivalent HFMD (hand foot and mouth disease), high-dose influenza, and inactivated rabies monoclonal antibody vaccine are in the pre-clinical stage. Liaoning Chengda Biotechnology Co.,Ltd. was founded in 2002 and is headquartered in Shenyang, China. Liaoning…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -82%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.